.svg){kind=small}
Inotrem SA, a biotechnology company specializing in the control of acute inflammatory syndromes, such as septic shock, announced today the successful completion of the first clinical trial of Motrem in healthy volunteers.The principal objective of this first in-man phase I clinical trial, conducted on a double-blind, randomized, placebo-controlled basis, was to evaluate Motrem’s safety, tolerance and pharmacokinetics.
.avif)
Latest news
Richmond Pharmacology Welcomes Back Dr Edward Jackson as Medical Director
November 3, 2025
Richmond Pharmacology is pleased to announce the return of Dr Edward Jackson, who re-joins the organisation as Medical Director.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
